Business Wire

LTIMindtree Delivers 1.8% QoQ and 5.6% YoY Revenue Growth in CC

16.1.2025 15:11:00 CET | Business Wire | Press release

Share

Historic high order inflow at USD 1.68 bn, up 29% sequentially Third consecutive quarter of employee addition of over 2,300

LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced its consolidated results today for the third quarter ended Dec 31, 2024, as approved by its Board of Directors.

“We closed Q3FY25 with a revenue of USD 1.14 billion, registering a sequential growth of 1.8% in constant currency and 1.1% in USD terms. Our differentiated AI strategy has helped us record our highest-ever order inflow of USD 1.68 billion, laying the foundation for future growth. Our ongoing investments in AI, including new partnerships and specializations, and accolades, support our efforts to continue growing as we enter CY25.”
- Debashis Chatterjee, Chief Executive Officer and Managing Director

Key financial highlights:

Quarter ended Dec 31, 2024

In USD:

- Revenue at $1,138.7 million (+1.1% Q-o-Q / +5.1% Y-o-Y)
- Operating Margin (EBIT) at 13.8%
- Net profit at $128.1 million (-14.3% Q-o-Q / -8.8% Y-o-Y)

In INR:

- Revenue at Rs 96,609 million (+2.4% Q-o-Q / +7.1% Y-o-Y)
- Net profit at Rs 10,867 million (-13.2% Q-o-Q / -7.1% Y-o-Y)

Other highlights:

Clients:

- 742 active clients as of Dec 31, 2024
- $5 million+ clients increased by 3 on a Y-o-Y basis, total 152
- $10 million+ clients increased by 1 on a Y-o-Y basis, total 90
- $50 million+ clients increased by 1 on a Y-o-Y basis, total 13

People:

- 86,800 professionals as of Dec 31, 2024. Added 2,362 in Q3
- Trailing 12 months attrition was 14.3%

Deal Wins

AI in Everything Deal Wins

  • A global manufacturer chose LTIMindtree to manage its end-to-end IT landscape using LTIMindtree’s ‘AI in Operations’ platform.
  • A leading global investment firm has selected LTIMindtree’s proprietary ‘AI in Infrastructure’ platform to manage its end-to-end infrastructure services.
  • A leading commercial property and casualty insurance management company selects LTIMindtree to provide end-to-end services for Duck Creek Suite.
  • A Middle East Nuclear Energy company chose for its end-to-end IT landscape, leveraging our ‘AI in Operations’ platform.
  • A leading Middle East Oil and Gas major has partnered with LTIMindtree to implement AI in Cloud operations.
  • Headquartered in New York, a leading provider of credit ratings chose LTIMindtree to implement AI in Application Managed Services.

Everything for AI Deal Wins

  • A state-owned insurance company selected LTIMindtree to implement data fabric and development of AI use cases, including data governance.
  • A leading US-headquartered software company that provides enterprise cloud computing solutions has entrusted LTIMindtree with managing their NextGen data fabric.
  • A leading Middle East Oil and Gas major has partnered with LTIMindtree to implement an advanced data governance platform.

Partnerships

  • LTIMindtree attained AWS GenAI competency, consequently strengthening its expertise in GenAI on AWS, including Amazon Bedrock and Quicksight. This is one of the most sought-after competencies amongst all AWS partners and marks LTIMindtree’s 11th AWS Specialization. This achievement further enhances LTIMindtree’s overall credibility in AI Innovation with AWS.
  • LTIMindtree and Microsoft Join Forces to Supercharge AI Innovation and Digital Transformation for Global Enterprises by utilizing Microsoft's advanced technologies like 365 Copilot and Canvas Sunshine.
  • LTIMindtree launched a comprehensive 360-degree solution for Oracle Database Migration to Azure Cloud, ensuring a smooth transition, minimal downtime, and optimized performance.
  • LTIMindtree achieved ITOM visibility ServiceNow's Product Line Achievements (PLAs). PLAs allow a partner to showcase their expertise and commitment to excellent customer service. These achievements serve as badges of honour in the ServiceNow community and will enhance LTIMindtree’s proposition to impress upon clients.
  • LTIMindtree was conferred Boomi’s Asia Partner of the Year Award at the 2024 APJ Partner Summit. This award highlights our expertise in integrating Boomi’s technology to drive digital transformation with innovative AI solutions.

Recognitions

  • LTIMindtree recognized in Forrester’s ‘The Customer Analytics Service Provider Landscape, Q1 2025’.
  • LTIMindtree recognized in Forrester’s ‘The Application Modernization and Multicloud Managed Services Landscape, Q4 2024’.
  • LTIMindtree recognized in Forrester’s ‘The Automation Fabric Services Wave, Q4 2024'.
  • LTIMindtree recognized in Forrester’s ‘The Business Intelligence Platforms Landscape, Q4 2024’.
  • LTIMindtree Recognized as an ‘Enterprise Innovator’ in HFS Horizons: ‘AADA Quadfecta Services for the Generative Enterprise, 2024’.
  • LTIMindtree Recognized as an ‘Enterprise Innovator’ in HFS Horizons: ‘IoT Service Providers, 2024’.
  • LTIMindtree Recognized as a ‘Major Contender’ in Everest Group: ‘Microsoft Azure Services PEAK Matrix® Assessment 2024’.
  • LTIMindtree Recognized as a ‘Major Contender’ in Everest Group: ‘Data and Analytics (D&A) Services PEAK Matrix® Assessment 2024’.
  • LTIMindtree Recognized as a ‘Major Contender’ in Everest Group: ‘Quality Engineering (QE) Services for AI Applications and Systems PEAK Matrix® Assessment 2024’.
  • LTIMindtree Recognized as a ‘Major Contender’ in Everest Group: ‘AWS Services PEAK Matrix® Assessment 2024’.
  • LTIMindtree Recognized as a ‘Major Contender’ in Everest Group: ‘Google Cloud Services PEAK Matrix® Assessment 2024’.
  • LTIMindtree Recognized as a ‘Major Contender’ in Everest Group: ‘Digital Transformation Consulting Services PEAK Matrix® Assessment 2024 – Europe’.
  • LTIMindtree Recognized as a ‘Major Contender’ in Everest Group: ‘Digital Transformation Consulting Change Management PEAK Matrix® Assessment 2024’.
  • LTIMindtree Recognized as a ‘Major Contender’ in Everest Group: ‘Artificial Intelligence and Generative AI Services PEAK Matrix® Assessment 2024’.
  • LTIMindtree Recognized as a ‘Major Contender’ in Everest Group: ‘CyberSecurity Services Europe PEAK Matrix® Assessment 2024’.
  • LTIMindtree Recognized as a ‘Major Contender’ in Everest Group: ‘Healthcare Provider Digital Services PEAK Matrix® Assessment 2024’.
  • LTIMindtree Positioned as a ‘Visionary’ in 2024 Gartner® Magic Quadrant™ for Cloud ERP Services.

*GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in our research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About LTIMindtree

LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 86,000+ talented and entrepreneurial professionals across more than 40 countries, LTIMindtree — a Larsen & Toubro Group company — solves the most complex business challenges and delivers transformation at scale. For more information, please visit https://www.ltimindtree.com/.

Earnings Conference Call

Universal Dial-in

+91 22 6280 1157
+91 22 7115 8058

 

International Toll Free

USA
UK
Singapore
Hong Kong

: 18667462133
: 08081011573
: 8001012045
: 800964448

Replay of Conference Call

Available after 1 hour from the call end time until Jan 17th, 2025
Playback Code: 67217
Dial-in Number: India +91 22 71945757

Audio Webcast
The audio from the conference call will be available online through a webcast and can be accessed at the following link: Click here for Audio Webcast

Click here for your DiamondPass™

DiamondPass™ is a Premium Service that enables you to connect to your conference call without having to wait for an operator.
If you have a DiamondPass™, click the above link to associate your pin and receive the access details for this conference. If you do not have a DiamondPass™, please register through the link and you will receive your DiamondPass™ for this conference.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250116590919/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye